The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

New research has suggested that vaccination of pregnant women has been linked to a drop in newborns being admitted to ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being ...

A vaccine in the Respiratory Syncytial Virus Infection pipeline presents a cost-effective solution to reducing the burden of RSV, as current options for both prevention and treatment are limited ...